1. Metformin Increases the Response of Cholangiocarcinoma Cells to Gemcitabine by Suppressing Pyruvate Kinase M2 to Activate Mitochondrial Apoptosis
   Haishan Deng et al, 2024, Digestive Diseases and Sciences CrossRef
2. Research advances of intracellular mechanisms underlying gemcitabine resistance in pancreatic cancer
   Zong-Ting Gu et al, 2020, World Chinese Journal of Digestology CrossRef
3. FASN promotes gallbladder cancer progression and reduces cancer cell sensitivity to gemcitabine through PI3K/AKT signaling
   Haihong Cheng et al, 2023, Drug Discoveries & Therapeutics CrossRef
4. Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer
   Duancheng Guo et al, 2023, Acta Biochimica et Biophysica Sinica CrossRef
5. MiR-486-3p was downregulated at microRNA profiling of adrenals of multiple endocrine neoplasia type 1 mice, and inhibited human adrenocortical carcinoma cell lines
   Su-Chen Li et al, 2021, Scientific Reports CrossRef
6. PKM2 is not required for pancreatic ductal adenocarcinoma
   Alissandra L Hillis et al, 2018, Cancer & Metabolism CrossRef
7. Oncometabolites in pancreatic cancer: Strategies and its implications
   Arunima Maiti et al, 2024, World Journal of Experimental Medicine CrossRef
8. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma
   Abudureyimu Tuerhong et al, 2021, Cellular and Molecular Life Sciences CrossRef
9. The role of metabolic reprogramming in pancreatic cancer chemoresistance
   Chang Liu et al, 2023, Frontiers in Pharmacology CrossRef
10. Hydrogen Sulfide Improves Lipid Accumulation in Nannochloropsis oceanica through Metabolic Regulation of Carbon Allocation and Energy Supply
    Jun Cheng et al, 2020, ACS Sustainable Chemistry & Engineering CrossRef